Market Brief

The articles are produced in Chinese only.

Author

倪國權先生 (Alex Ni)
助理經理

曾任職鋼材交易員及廣告公司主任,所以特別喜歡研究資源類及消費類股票。歡迎來電賜教或交流心得。
Phone:
22776779

HUMAN HEALTH HOLDING LTD.(1419.HK)

Monday, June 15, 2026 Views35

Commentary: 

Stock: 

HUMAN HEALTH HOLDING LTD. 

 

1 Month H/L: 

0.76– 0.80

Stock Code: 

1419.HK 

 

52 week H/L: 

0.74 – 1.35

Market Cap.: 

HKD 0.296 B 

 

Listing date: 

01/04/2016

Stock Outstanding: 

379,552,233 shares 

 

Listing price: 

1.38

P/E (TTM): 

11.304x 

 

Chairman & CEO: 

Chan Kin Ping

Dividend: 

0.03 (End of Year) 

 

Major Shareholdes: 

1. Chan Kin Ping & Family – 68.29%

Dividend  

Yield(annualised):

3.846%

     
         


The Human Health Holdings Limited 2025 annual report (year ended 30 June 2025), presenting financial and operational highlights amid a challenging macroeconomic environment in Hong Kong, nevertheless, the company achieved stable growth in revenue as well as profit. 

According to the annual report of the company, there are some strategic projects and initiatives the company undertake that contribute to the company's revenue and profit growth in FY2025: 

1) Acquisition of Monarch Detanl Clinic Limited. The project was completed in February 2025; After the completion, the company's dental service revenue grew 15.9% YoY, the accelerated market penetration in the high-demand dental care segment, created cross referral opportunities with general practice and specialist services. 

2) Specialist services expansion, Polyeye brand development. The company introduced an advanced diagnostic and treatment technologies through the Polyeye brand that provide high margin services. The initiatives enhanced referral pathways between GP clinics and specialist centers within the group. The specialist service became the fastest-growing segment and recorded a reveue surged 23.8% YoY,  

The company delivered resilient 2025 results - with 9.1% revenue growth as well as 8.9% in profit growth underpinned by strategic acquisitions, specialist services expansion and operational discipline. While acknowledging the marco uncertainties and competitive pressures, the Board remains cautiously optimistic, positioning the Group to capture growth opportunites driven by againg demographics, rising health awareness and continued public-private collaboration. 

「註:本人倪國權為證監會持牌人士。截至本評論文章發表日止,本人及 / 或其有聯繫者並無持有全部提及之証券的所有相關財務權益。」 ; Or ” I, Ni Kwok Kuen Alex, am a licensed person under the Securities and Futures Commission. Until the date this commentary was published, neither I and/or my affiliates are the beneficiary of the securities mentioned herein or are entitled to any financial interests in relation thereto. “

 
This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk. Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email : businessenquiry@phillip.com.hk

Enquiry & Support
Branches
The Complaint Procedures
About Us
Phillip Securities Group
Join Us
Phillip Network
Phillip Post
Phillip Channel
Latest Promotion
新闻稿
E-Check
Login
Investor Notes
Free Subscribe
Contact Us